Trial Profile
A Double-blinded, Randomised, Placebo Controlled, Five-way Crossover Study With One Positive Control (Open-label) (Moxifloxacin) to Assess the Influence of Oral Single Dose KUC 7483 BS (40 mg, 80 mg, 160 mg, 320 mg) on the QT/QTc Interval of the ECG in Healthy Male and Female Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Oct 2014
Price :
$35
*
At a glance
- Drugs Ritobegron (Primary)
- Indications Overactive bladder
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 11 Oct 2014 New trial record